Chimeric Therapeutics Ltd. ( (AU:CHM) ) has provided an update.
Chimeric Therapeutics announced significant progress in its clinical trials for the quarter ending March 31, 2025. The CHM CORE-NK studies have advanced with patient recruitment and dosing at prominent U.S. cancer centers, while the CHM CDH17 CAR-T trial, targeting advanced cancers, has expanded to include the University of Chicago Medicine. This trial is notable for its pioneering approach as the first anti-CDH17-directed CAR-T therapy, showing promising preclinical results. The company also secured $4 million in non-dilutive funding to support these developments, indicating strong financial backing and potential for impactful advancements in cancer treatment.
More about Chimeric Therapeutics Ltd.
Chimeric Therapeutics Ltd. is an Australian company specializing in cell therapy. The company focuses on developing innovative CAR-T cell therapies targeting various cancer types, including colorectal, gastric, and neuroendocrine tumors.
Technical Sentiment Signal: Buy
Current Market Cap: A$11.34M
Learn more about CHM stock on TipRanks’ Stock Analysis page.